Keywords: Anticancer Natural Products, Leading Compound, Bioactivity-guided Isolation, Potential Cancer Targets, Target Recognition Technology Important Note: All contributions to this Research Topic ...
THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activity Data presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 ...
today announced encouraging initial clinical data from the ongoing Phase I study of its lead compound THE001 in patients with heavily pre-treated, locally advanced unresectable or metastatic soft ...
Munich, Germany – November 19, 2024 – Thermosome, a drug development company focused on targeted tumor therapies, today announced encouraging initial clinical data from the ongoing Phase I study of ...